- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01086748
A Study in Schizophrenia Patients
September 18, 2012 updated by: Eli Lilly and Company
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
880
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zagreb, Croatia, 10090
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Khotkovo, Russian Federation, 127025
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Lipetsk, Russian Federation, 399007
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Moscow, Russian Federation, 115522
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nizhniy Novgorod, Russian Federation, 603155
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Saint Petersburg, Russian Federation, 190121
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Samara, Russian Federation, 443016
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Saratov, Russian Federation, 410028
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Yaroslavl, Russian Federation, 150003
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
California
-
Escondido, California, United States, 92025
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Garden Grove, California, United States, 92845
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Paramount, California, United States, 90723
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hollywood, Florida, United States, 33021
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hoffman Estates, Illinois, United States, 60169
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70629
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Shreveport, Louisiana, United States, 71104
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Mississippi
-
Flowood, Mississippi, United States, 39232
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New York
-
Cedarhurst, New York, United States, 11516
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Rochester, New York, United States, 14615
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19131
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Texas
-
Austin, Texas, United States, 78754
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Desoto, Texas, United States, 75115
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Houston, Texas, United States, 77008
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; APA 2000) (Disorganized, 295.10; Catatonic, 295.20; Paranoid 295.30; or Undifferentiated, 295.90) and confirmed by the Structured Clinical Interview for DSM-IV-TR (SCID).
- Non pregnant female patients who agree to use acceptable birth control
- At entry to the study must be considered moderately ill in the opinion of the investigator
- Willing to participate in a minimum of 3 weeks of inpatient hospitalization and this must be appropriate for the patient in the clinical judgment of the investigator.
- 1 year history of Schizophrenia prior to entering the study
- At study entry patients with a history of antipsychotic treatment must have a lifetime history of at least one hospitalization for the treatment of schizophrenia, not including the hospitalization required for study. Patients who have never taken antipsychotic treatment may enter the study even without a history of hospitalization.
- At study entry patients with a history of antipsychotic treatment must have a history of at least one episode of illness exacerbation requiring an intensification of treatment intervention or care in the last 2 years, not including the present episode of illness. Patients who have never taken antipsychotic treatment may enter the study without a past history of illness exacerbation and intensification of treatment in the last 2 years.
- At study entry patients must have experienced an exacerbation of illness within the 2 weeks prior to entering the study, leading to an intensification of psychiatric care in the opinion of the investigator. If exacerbation occurs in patients who are presently hospitalized, the patient must not have been hospitalized longer than 60 days at entry of the study
Exclusion Criteria:
- Participated in any clinical trial with any pharmacological treatment intervention for which they received a study-related medication in the 6 months prior to visit 1
- Previously completed or withdrawn from this study, or any other study investigating LY2140023 or any predecessor molecules with glutamatergic activity.
- Treatment with clozapine at doses greater than 200 mg daily within 12 months prior to entering the study, or who have received any clozapine at all during the month before entering the study
- Patients currently receiving treatment (within 1 dosing interval, minimum of 4 weeks, prior entering the study) with a depot formulation of an antipsychotic medication.
- Patients who are currently suicidal.
- Females who are pregnant, nursing, or who intend to become pregnant within 30 days of completing the study.
- Patients with uncorrected narrow-angle glaucoma, uncontrolled diabetes, certain diseases of the liver, renal insufficiency, uncontrolled thyroid condition or other serious or unstable illnesses
- Have a history of one or more seizures, except for those who experienced a single simple febrile seizure between ages 6 months and 5 years
- Patients are excluded if their, biological father, mother, brother, sister, or child has a history of idiopathic epilepsy.
- Within 1 year of study enrollment, patients have a history of central nervous system infection, uncontrolled migraine, transient ischemic attack (TIA), or head trauma with loss of consciousness or a post-concussive
Patients are excluded if they have a lifetime history of any of the following:
- head trauma, stroke, or CNS infection with persistent neurological deficit (focal or diffuse);
- brain surgery;
- an electroencephalogram with paroxysmal (epileptiform) activity, or
- brain structural lesion, including developmental abnormalities, as determined by examination or previous neuroimaging studies that are consistent with a diagnosable neurological disease or syndrome.
- Electroconvulsive therapy (ECT) within 3 months of entering the study or who will have ECT at any time during the study.
- Leukopenia
- Medical history of Human Immunodeficiency Virus positive (HIV+) status.
- Higher than normal blood prolactin levels
- Certain electrocardiogram results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 160 mg LY2140023
80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
|
Administered orally.
|
ACTIVE_COMPARATOR: 4 mg Risperidone
2 mg risperidone administered orally, BID for up to 7 weeks.
|
Administered orally.
|
PLACEBO_COMPARATOR: Placebo
Placebo administered orally, BID for up to 7 weeks.
|
Administered orally.
|
EXPERIMENTAL: 80 mg LY2140023
40 mg LY2140023 administered orally, BID for up to 7 weeks.
|
Administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
A change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in overall schizophrenia population
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in a genetic subgroup of schizophrenia patients
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
A change from baseline in the Personal and Social Performance (PSP) score in the overall schizophrenia population
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in the Personal and Social Performance (PSP) score in a genetic subgroup of schizophrenia patients
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in the PANSS positive scale
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in the PANSS negative scale
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in PANSS General Psychopathology subscale
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in the Clinical Global Impression-Severity Scale (CGI-S)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in the 16-item Negative Symptoms Assessment (NSA-16)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in the Montgomery-Ǻsberg Depression Rating Scale (MADRS)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
PANSS total score
Time Frame: up to 7 weeks of treatment
|
up to 7 weeks of treatment
|
A change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score in a female patients
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Rate of discontinuation
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Time to discontinuation
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline on the EuroQol - 5 Dimensions (EQ-5D) Questionnaire
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline on resource utilization, as measured by the Schizophrenia Resource Use Model (S-RUM)
Time Frame: Baseline up to 7 weeks of treatment
|
Baseline up to 7 weeks of treatment
|
A change from baseline on functional capacity, as measured by the Subjective Well-Being Under Neuroleptic Treatment Scale - Short Form (SWN-S)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in Barnes Akathisia Scale (BAS)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in Simpson-Angus Scale (SAS)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in Abnormal Involuntary Movement Scale (AIMS)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A mean change from baseline in Prolactin levels
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in weight
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Number of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to 7 weeks of treatment
|
Up to 7 weeks of treatment
|
Change from baseline in electrocardiogram parameters
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in neurological examination
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Statistically different changes in vital signs from baseline
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Statistically different changes in lab values from baseline
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Population pharmacokinetics (PK) of LY2140023
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
A change from baseline in Columbia- Suicide Severity Rating Scale (C-SSRS)
Time Frame: baseline, up to 7 weeks of treatment
|
baseline, up to 7 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016. Epub 2015 Mar 19.
- Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, Brenner R, Rayle TJ, Nisenbaum L, Zhao F, Gomez JC. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014 Dec 10;14:351. doi: 10.1186/s12888-014-0351-3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (ACTUAL)
May 1, 2012
Study Completion (ACTUAL)
May 1, 2012
Study Registration Dates
First Submitted
March 12, 2010
First Submitted That Met QC Criteria
March 12, 2010
First Posted (ESTIMATE)
March 15, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 25, 2012
Last Update Submitted That Met QC Criteria
September 18, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Risperidone
Other Study ID Numbers
- 11958
- H8Y-MC-HBBM (OTHER: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States